Biosimilars Global Market Report 2024 -By Growth, Share, Demand, Trends, Outlook By 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Biosimilars Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The biosimilars market size has grown rapidly in recent years. It will grow from $15.86 billion in 2023 to $18.85 billion in 2024 at a compound annual growth rate (CAGR) of 18.9%. The growth in the historic period can be attributed to an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical r&d expenditure, increased healthcare expenditure, growing government initiatives, strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration..

The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $35.81 billion in 2028 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (g-csf), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. . Major trends in the forecast period include focus on robust r&d activities for the development of effective and innovative drugs, focus on focus on m&a growth strategies, focus on establishing strategic partnerships, focus on increasing investments and focus on artificial intelligence..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

Market Segmentation:
The biosimilars market covered in this report is segmented -
1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others
2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins
3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications

Major Driver - Rising Prevalence Of Chronic Diseases Sparks Growth In The Biosimilars Market
The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market. Long working hours, limited physical activity, and unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biosimilars, thus driving the biosimilars market.

Competitive Landscape:
Major companies operating in the biosimilars market report are Amgen, Pfizer, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Biocon, Celltrion, Inc., Coherus Biosciences, Elli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, HARMONIE MEDICAL SERVICE Saint-Benoît, INSULET FRANCE SAS Paris, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Top Trend - Innovative Product Launched Enhance Biosimilars Market
Major companies in the biosimilars market focus on developing innovative products to gain a competitive edge in the market. AMJEVITA is the first U.S. biosimilar to Humira, a medicine used by more than a million patients living with certain serious inflammatory diseases. For instance, in January 2023, Amgen Inc., a US-based biotechnology company, launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab), which is now available in the US. AMJEVITA (40 mg) is available at a list price (wholesale acquisition cost) 55% below the current Humira list price. AMJEVITA is also available at a list price 5% below the current Humira list price.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Biosimilars Market Characteristics
3. Biosimilars Market Trends And Strategies
4. Biosimilars Market - Macro Economic Scenario
5. Biosimilars Market Size And Growth
…..
27. Biosimilars Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model"

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.